Great news as the FDA approved a new Alzheimer's treatment last week! https://lnkd.in/gxcBBbfb #FDA #Pharma #SciSearch
Scientific Search’s Post
More Relevant Posts
-
The FDA has reviewed Eli Lilly's Alzheimer's drug, Donanemab 🔬🧠 This drug targets and removes toxic beta-amyloid plaques in the brain, similar to other treatments like Leqembi. If approved, Donanemab could mark a significant advancement in slowing the progression of Alzheimer's. Stay tuned for updates as the FDA advisory panel endorses its potential approval! 🔗 Source in comments #AlzheimersResearch #EliLilly #Donanemab #FDAApproval #MedicalAdvancements
To view or add a comment, sign in
-
-
How can #biopharma companies tell their story to achieve #earnedmedia success? Look no further than this story on Eli Lilly’s Alzheimer’s drug donanemab. - They provided access to the scientists to discuss the long journey with many challenges and successes of researching the disease and taking the drug through clinical trials. - They provided anecdotes dating back three decades that demonstrated their long-term commitment to treating Alzheimer’s even when there were doubts they would succeed. - They shared forward-looking messaging that conveys understanding that there is much more work to do and that they are positioned to continue to lead in this area. #Mediarelations #HealthCommunications
To view or add a comment, sign in
-
WORLD ALZHEIMER'S DAY 2023 🌍 The theme for World Alzheimer's Day 2023, "Never Too Early, Never Too Late," emphasizes the crucial importance of identifying risk factors and embracing proactive measures to delay and prevent the onset of the disease. It serves as a call to action, encouraging individuals, families, and communities to take control of their cognitive well-being. Let us raise awareness, share knowledge, and take meaningful steps towards a future where Alzheimer's impact is significantly reduced. #PharmaScroll #healthcare #pharmaceutical #alzheimers #worldalzheimersday #alzheimersawareness #nevertooearly #nevertoolate #alzheimersawarenessmonth
To view or add a comment, sign in
-
-
The FDA has made a pivotal move in its approach to Alzheimer's drug development, suggesting that amyloid reduction can now serve as a surrogate endpoint for predicting clinical benefits. This comes after years of debate about the relationship between amyloid reduction and cognitive health improvements in Alzheimer's patients. With new guidelines released, the FDA is paving the way for more innovative treatments following the controversial approval of Aduhelm and the recent focus on Eisai and Biogen’s Leqembi. It's a significant moment that could accelerate the availability of new therapies for those in the early stages of Alzheimer's disease. #FDA #AmyloidReduction https://lnkd.in/eiagmFTM
To view or add a comment, sign in
-
-
1️⃣ Eisai US targets US launch for new dementia treatment, aiming to address cognitive decline 💊 2️⃣ Judge dismisses block on Johnson & Johnson talc settlement, clearing the way for resolution ⚖️ 3️⃣ Biogen wins #Tecfidera patent dispute, securing its multiple sclerosis treatment market 💼 4️⃣ #PresidentTinubu cuts drug prices in #Nigeria, boosting local healthcare access 🏥 📌 Read more news- https://lnkd.in/dh36nZ8Y Stay tuned for more exciting updates in biopharma! 🚀 #PharmaNews #Biotech #HealthcareInnovation #DrugDevelopment #LegalUpdates #PharmaNow
To view or add a comment, sign in
-
I am so excited to see progress that is truly focused on patient and helping them through their disease journey. I still question why a similar proxy cannot be offered to patient’s in trials. Why should they not have a digital interface that allows them and their loved ones to plan and understand where they are in their trial journey. What about a personalized dashboard for vital information at their fingertips?
It’s early days, but this dementia-related initiative from Eisai hints at what the future could look like for #biopharma: Groundbreaking drugs combined with an ecosystem of #digitalhealth and other assets that support patients across their entire disease journey—regardless of whether they’re on branded treatment not.
Eisai launches 'digital business' Theoria to build out a dementia ecosystem for patients
fiercepharma.com
To view or add a comment, sign in
-
Delivering the power of customer data through insights to stop guessing and start impressing | The coach with the good playlist |
When my dad retired late last year after a remarkable 50+ year career as a parish prosecutor, his biggest fear was facing cognitive decline and, ultimately, Alzheimer's. With an estimated 6.3 million Americans affected by this disease, his concerns are all too real. As someone who is monitoring the wellbeing of aging parents, understanding the efforts to find a cure for Alzheimer's is top of mind. This year alone, there are 171 ongoing studies and 134 drugs related to Alzheimer’s in clinical trials. With big names like Eli Lilly, AbbVie, and Sanofi leading the charge in new clinical testing and trials, there are several innovative players who are making waves in the treatment landscape. Here are a few that caught my eye: Alzheon, Inc. | Preserving Future Memories: Developing ALZ-801, the first oral Alzheimer’s drug. Otsuka Pharmaceutical Companies (U.S.): Achieved FDA approval for Rexulti, the first approved treatment for agitation in Alzheimer’s dementia patients. On a personal note, my dad continues to lead an active lifestyle—he’s still doing triathlons at 78! To keep his mind sharp, he's enrolling in a writing course at ULL this fall. Pharma and healthcare friends: any new developments that you are watching? Drop them in the comments 👇 #AlzheimersResearch #PharmaInnovation #ClinicalTrials #Healthcare #MarketResearch #AlzheimersAwarenessMonth #PharmaIndustry
To view or add a comment, sign in
-
-
Merck KGaA, Darmstadt, Germany Highlights the P-III Results for Evobrutinib to Treat of Relapsing Multiple Sclerosis (RMS) #merckkgaa #evobrutinib #relapsingmultiplesclerosis #clinicaltrials #phase3 #evolution #evolutionrms1 #evolutionrms2 #teriflunomide #safety #efficacy #patients #rms #antibody #cytokines
Merck KGaA Reports Results for Evobrutinib in P-III Trial for the Treatment of Relapsing Multiple Sclerosis (RMS)
pharmashots.com
To view or add a comment, sign in
-
#ACTRIMS2024: #BMS presented long-term data of #Zeposia in patients with Relapsing Forms of #MultipleSclerosis https://lnkd.in/gxbGkBVj #BREAKING #news #pharma #pharmaceutical #Science #TeleMedicine #media #medicine #healthcare #MedComms #Medical #PatientSafety #ACTRIMS
Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) | 2024 | iPharmaCenter
ipharmacenter.com
To view or add a comment, sign in
-
Thoughts on this? >> Labcorp expands Alzheimer’s blood tests for doctors and drugmakers >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #healthcare #productmarketing #biotech #pharmaceutical #pharma
Labcorp expands Alzheimer’s blood tests for doctors and drugmakers
https://endpts.com
To view or add a comment, sign in